Alumis (ALMS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Alumis

NasdaqGS•Healthcare•Biotechnology

$7.94-0.46(-0.05%)Pre-market

Market Cap

$992.15M

P/S

134.1x

P/B

2.2x

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

How this company scores

WeakMetricSide Score: 25/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (0/25).

Profitability0/25

Growth4/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 134.1x5y range 17.2x – 300.8x

Currently above its 6-quarter median.

P/B · 2.2x5y range 0.7x – 4.5x

Currently near its 8-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $992.15M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $7.40M
Q. Revenue: $1.66M
TTM EBITDA: $-455.50M
TTM Op. Income: $-459.00M
Q. Op. Income: $-148.85M
TTM Net Income: $-438.96M
Q. Net Income: $-142.22M
EPS: $-1.11
Shares Out.: $127.69M

$7.40M in TTM revenue declined 63.1% YoY, reaching $1.66M last quarter. TTM EBITDA of $-455.50M and TTM operating income of $-459.00M show growth is flowing through to the bottom line. However, net income is negative at $438.96M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -8908.2%
Op. Margin: -8956.4%
Net Margin: -8557.2%

Op. margin of -8956.4% is down 3684.8% YoY — costs are rising relative to revenue. Net margin at -8557.2% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 134.1x
P/B Ratio: 2.2x

P/S of 134.1x and P/B of 2.2x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $560.62M
Cash: $63.71M
Long-Term Debt: N/A
Book Value: $452.16M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-81.50M
TTM Free Cash Flow: $-351.80M
FCF Margin: -4755.3%
FCF / Net Income: 0.8

TTM FCF of $-351.80M on $-81.50M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 1% — an improving trend.